SeraNovo names Michiel Van Speybroeck as head of development for clinical studies

SeraNovoa pharmaceutical company with a breakthrough proprietary formulation platform for enhancing drug bioavailability has appointed Dr Michiel Van Speybroeck to the role of Chief Development Officer (CDO) with immediate effect.

Niall Hodgins, CEO of SeraNovo said: “We are thrilled to have someone of Michiel’s technical background and industry experience join SeraNovo. Our work in 2020 proved the value of our technology for solving one of the most difficult problems in the pharmaceutical industry, I have every confidence Michiel is the person most suited to lead the development of the company going forward.”

Dr Joost Holthuis, Chairman of the SeraNovo Board said: “On behalf of the board  I am pleased to welcome Michiel to SeraNovo. Michiel joins the management team at a pivotal time now the company is expanding its technology platform, projects and client base.”

Michiel Van Speybroeck said: “I am impressed by the performance of SeraNovo’s technology and the progress the company has been able to make in such a short period of time. I am looking forward to joining this young, dynamic team and to contributing to the further development, scale-up and commercialisation of a technology that will prevent promising drug candidates from falling from the pipeline due to solubility limitations.”